Published by Josh White on 8th August 2024
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation Oxford Biomedica reported a strong first-half trading performance in an update on Thursday, with revenue expected to reach £50m.
URL: http://www.digitallook.com/dl/news/story/34480823/...